ATE432983T1 - Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden - Google Patents

Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden

Info

Publication number
ATE432983T1
ATE432983T1 AT98945923T AT98945923T ATE432983T1 AT E432983 T1 ATE432983 T1 AT E432983T1 AT 98945923 T AT98945923 T AT 98945923T AT 98945923 T AT98945923 T AT 98945923T AT E432983 T1 ATE432983 T1 AT E432983T1
Authority
AT
Austria
Prior art keywords
mage
hla class
molecules
peptides
peptides presented
Prior art date
Application number
AT98945923T
Other languages
English (en)
Inventor
Kris Thielemans
Carlo Heirman
Jurgen Corthals
Pascal Chaux
Vincent Stroobant
Thierry Boon-Falleur
Der Bruggen Pierre Van
Rosalie Luiten
Original Assignee
Ludwig Inst For Cancer Res Ltd
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst For Cancer Res Ltd, Univ Bruxelles filed Critical Ludwig Inst For Cancer Res Ltd
Application granted granted Critical
Publication of ATE432983T1 publication Critical patent/ATE432983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98945923T 1997-09-12 1998-09-04 Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden ATE432983T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/928,615 US5965535A (en) 1997-09-12 1997-09-12 Mage-3 peptides presented by HLA class II molecules
PCT/US1998/018601 WO1999014326A1 (en) 1997-09-12 1998-09-04 Mage-3 peptides presented by hla class ii molecules

Publications (1)

Publication Number Publication Date
ATE432983T1 true ATE432983T1 (de) 2009-06-15

Family

ID=25456537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945923T ATE432983T1 (de) 1997-09-12 1998-09-04 Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden

Country Status (9)

Country Link
US (2) US5965535A (de)
EP (1) EP1012283B1 (de)
JP (1) JP4106179B2 (de)
AT (1) ATE432983T1 (de)
AU (1) AU757368B2 (de)
CA (1) CA2303063C (de)
DE (1) DE69840868D1 (de)
WO (1) WO1999014326A1 (de)
ZA (1) ZA988124B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533295T3 (de) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
PT1584685E (pt) 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
EP1117679B9 (de) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
IT1312568B1 (it) * 1999-05-21 2002-04-22 Genera Spa Peptidi immunogenici e loro uso.
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
CN1402782A (zh) * 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
US6605711B1 (en) * 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
ATE513913T1 (de) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7803382B2 (en) 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
EP2284535A1 (de) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Heparine mit niedrigem Molekulargewicht
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
AU2003287557A1 (en) * 2002-11-07 2004-06-03 Lung-Ji Chang Modified dendritic cells
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US7858743B2 (en) * 2004-09-09 2010-12-28 Ludwig Institute For Cancer Research SSX-4 peptides presented by HLA class II molecules
WO2006045750A2 (en) * 2004-10-20 2006-05-04 Friedrich-Alexander- Universität Erlangen- Nürnberg T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
AU2010329551B2 (en) 2009-12-10 2016-02-11 Turnstone Limited Partnership Oncolytic rhabdovirus
US8435795B2 (en) 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
CN109893648A (zh) * 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015184224A1 (en) * 2014-05-30 2015-12-03 Academia Sinica Aptamer targeting mage-a3 peptide and uses thereof
WO2016103192A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
EP3419962A4 (de) 2016-02-26 2020-03-11 Auckland Uniservices Limited Aminosäure- und peptidkonjugate und konjugationsverfahren
US10441509B2 (en) * 2018-03-16 2019-10-15 Berkshire Biomedical, LLC Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019409D0 (en) * 1990-09-05 1990-10-17 Pfizer Ltd Therapeutic agents
US5139325A (en) * 1991-01-25 1992-08-18 Oksman Henry C Wide depth of focus power add to intraocular and contact lenses
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5348578A (en) * 1991-10-23 1994-09-20 Ppg Industries (France) S.A. Products obtained from the reaction of amine-diol and a polyfunctional substance and application of such products to electroapplicable cationic paint compositions
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5414610A (en) * 1993-06-21 1995-05-09 Ast Research, Inc. Universal power converter with single, shared power transformation circuit
US5696764A (en) * 1993-07-21 1997-12-09 Fujitsu Limited ATM exchange for monitoring congestion and allocating and transmitting bandwidth-guaranteed and non-bandwidth-guaranteed connection calls
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5886421A (en) * 1994-11-11 1999-03-23 Kabushiki Kaisha Tokai-Rika-Denki Seisakusho Vehicle start-up permission device and identification code registering method
DE4441903C1 (de) * 1994-11-24 1996-03-21 Siemens Ag Drucksensor
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
WO1997013858A2 (en) * 1995-10-12 1997-04-17 Chiron Corporation Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
EP2724617A1 (de) 2012-10-25 2014-04-30 Commissariat A L'energie Atomique Et Aux Energies Alternatives Verbindungen zum Abschwächen von Phosphatsterbesymptomen bei Pflanzen
US9603182B2 (en) 2013-03-14 2017-03-21 Qualcomm Incorporated Establishing reliable always-on packet data network connections

Also Published As

Publication number Publication date
US5965535A (en) 1999-10-12
AU757368B2 (en) 2003-02-20
DE69840868D1 (de) 2009-07-16
EP1012283B1 (de) 2009-06-03
AU9306198A (en) 1999-04-05
JP4106179B2 (ja) 2008-06-25
EP1012283A1 (de) 2000-06-28
US6369211B1 (en) 2002-04-09
JP2001516579A (ja) 2001-10-02
CA2303063C (en) 2009-11-24
CA2303063A1 (en) 1999-03-25
ZA988124B (en) 1999-03-05
WO1999014326A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
ATE432983T1 (de) Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
WO2002095051A3 (en) Mage-a3 peptides presented by hla class ii molecules
EP0796913A3 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
CY1109715T1 (el) IL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69839444D1 (de) Smad 6 und dessen anwendungen
NO984415D0 (no) Peptider med antiproliferative egenskaper
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
DE69935213D1 (de) Basb019 proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen
ATE341628T1 (de) Proteine und gene aus moraxella catarrhalis, antigene, antikörper, und verwendungen
NZ510812A (en) Novel peptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1012283

Country of ref document: EP